Lack of serum antibodies to the major HSV‐2 specified DNA‐binding protein before diagnosis of cervical neoplasia

Abstract

We report results based on a prospective case-control study within a cohort obtained by linking the Finnish Social Insurance Institutions Mobile Clinic Survey Registry and the Finnish Cancer Registry. The overall prevalence of herpes virus early antigen (ICSP 11/12) antibodies was similar in controls and in cervical neoplasia cases (consisting of invasive cervical carcinoma, ICC, and cervical intraepithelial neoplasia group III, CIN III cases). However, those CIN III cases, who after a long lag period (average 7 years after the blood sample was drawn) developed cervical neoplasia, had significantly lower antibody levels than did matched controls. Their ICSP 11/12 antibody levels became higher the shorter the lag period. The negative correlation between the ICSP 11/12 antibody levels and the lag period was most pronounced in the HSV-2 seropositive CIN III cases. In an analysis of cross-sectional case-control material from the Clinic of Obstetrics and Gynaecology, Tampere University Central Hospital, the patients with ICC had the highest ICSP 11/12 antibody levels. Statistically significant differences between cases and controls were not found. We conclude that in cervical neoplasia the kinetics of ICSP 11/12 antibody levels are determined by the malignant process itself. The cervical disease may selectively induce early viral antigens, thus giving rise to the antibody response described in this paper.